**Question:** Tildrakizumab was approved by FDA in 2018 for

A. Treatment of psoriasis
B. Treatment of asthma
C. Treatment of COVID-19
D. Treatment of hypertension

**Core Concept:**
Tildrakizumab is a monoclonal antibody that belongs to the class of drugs called interleukin (IL)-23 inhibitors. It was developed as a treatment for inflammatory skin conditions, specifically targeting the inflammatory pathway involved in psoriasis. Interleukin-23 is a cytokine that plays a crucial role in the immune response and inflammation, and inhibiting it can lead to reduced inflammation and skin lesions characteristic of psoriasis.

**Why the Correct Answer is Right:**
Tildrakizumab was approved by the FDA for the treatment of psoriasis because it effectively targets and inhibits the IL-23 cytokine, which is a key player in the pathogenesis of psoriasis. By blocking this cytokine, tildrakizumab reduces the excessive immune response and inflammation that leads to psoriatic lesions and symptoms.

**Why Each Wrong Option is Incorrect:**

A. Treatment of asthma: Tildrakizumab is not approved by the FDA for asthma treatment. Asthma is primarily managed with corticosteroids, leukotriene modulators, bronchodilators, and other targeted therapies that work on different pathways and mechanisms.

B. Treatment of hypertension: Tildrakizumab has no direct impact on blood pressure regulation or hypertension treatment. Hypertension is mainly managed with antihypertensive medications such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), calcium channel blockers, and diuretics, which target different mechanisms and receptors involved in blood pressure control.

C. Treatment of COVID-19: Tildrakizumab was not approved by the FDA for COVID-19 treatment. Currently, COVID-19 treatment includes a combination of antiviral medications, immunomodulatory drugs, oxygen therapy, and supportive care, targeting various aspects of the disease and its complications.

D. Treatment of hypertension: As mentioned above, Tildrakizumab has no direct impact on blood pressure regulation or hypertension treatment. Hypertension management includes medications targeting various mechanisms and receptors involved in blood pressure control.

**Clinical Pearl:**
Psoriasis is a chronic inflammatory skin condition characterized by abnormal immune response and excessive skin cell proliferation, leading to the formation of red, scaly patches on the skin. Tildrakizumab is a biologic agent that specifically targets the IL-23 cytokine, which plays a crucial role in the pathogenesis of psoriasis. By inhibiting IL-23, tildrakizumab helps in reducing inflammation and skin lesions in patients with psoriasis.

**Why Each Wrong Option is Incorrect:**

A. Treatment of asthma: As mentioned earlier, asthma is managed with corticosteroids, leukotriene modulators, and bronchodilators, which target different mechanisms and receptors involved in asthma pathogenesis. Tildrakizumab does not have a direct impact on asthma treatment.

B. Treatment of hypertension: As explained above, Tildrakizumab does